cancer
Phenotype Diagnostics – Novel method for risk assessment and treatment stratification in men with prostate cancer
Prostate cancer (PC) is a common and multifocal disease, with symptoms ranging from harmless to lethal. In Sweden, about 10000 new cases are diagnosed every year.
G4 Cancer Cure Project – Increased patient survival in breast cancer
Triple-negative breast cancer, a hard-to-treat cancer subtype more common in young women, needs improved drugs to increase patient survival. Our innovation, a small molecule that targets G-quadruplex DNA structures, will selectively eradicate triple-negative breast cancer cells, and thereby improve treatment.
Metacurum Biotech AB – Novel antibody treatment for metastatic cancers
MetaCurUm Biotech is developing a novel antibody treatment for metastatic cancers. The company´s drug development program is focused on transforming growth factor-beta (TGFβ) driven cancers, with the aim to optimize the treatment paradigms in aggressive forms of cancer with high unmet medical need such as prostate, lung, kidney, and endometrial cancer.
Medsens AB – exact real time prostate cancer diagnosis
By combining two different methods, Medsens AB aimed to offer a whole new tool for realtime microdiagnostics during prostate cancer surgery. Medsens, based on the work of Olof Lindahl och Kerstin Ramser, received support from UBI for three years. The company is put on hold but the research is ongoing.
Betulaceae Pharmaceuticals – improved quality of life during cancer
Our project goals aim at increased survival, improved quality of life and less suffering for cancer patients. Our novel chemical entities (NCE) can prevent over-activation of certain signaling pathways and are based on existing pharmaceuticals that are well tolerable and easy to produce. This will be a first in class drug with little side effects (known drug class), addressing cancer induced cachexia and suppression of the immune system.
Hiloprobe AB – improved colorectal cancer diagnostics
HiloProbe was a research-based company in the field of cancer diagnostics. HiloProbe developed ColoNode® – a biomarker test for the accurate detection and characterization of cancer cells in the lymph nodes of colorectal cancer patients. At the beginning of 2025, HiloProbe shut down its operations.